|1.||Mathew, Milly: 1 article (11/2015)|
|2.||Abraham, Georgi: 1 article (11/2015)|
|3.||Nagarajan, Prethivee: 1 article (11/2015)|
|4.||Reddy, Pooja P: 1 article (11/2015)|
|5.||Mehra, Nikita: 1 article (11/2015)|
|6.||Sundaram, Varun: 1 article (11/2015)|
|7.||Reddy, Yogesh N V: 1 article (11/2015)|
|8.||Reddy, Yuvaram N V: 1 article (11/2015)|
|9.||Ramachandran, A: 1 article (11/2015)|
|10.||Ali, Asik Ali Mohammed: 1 article (11/2015)|
|1.||Chronic Kidney Failure (Chronic Renal Failure)
09/01/2014 - "While the HLA-B8 antigen may be a susceptibility risk factor for development of ESRD, the HLA-A28, and HLA-DR11 antigens may be protective against development of ESRD in Kuwaiti population."
09/01/2014 - "The frequency of HLA-B8 antigen was significantly higher in ESRD patients (OR = 2.62, p = 0.001, pc = 0.038), and the frequency of HLA-A28, HLA-DR11 antigens was significantly higher in healthy controls (OR 0.42, p = 0.0001; pc = 0.0021, and OR = 0.44, p = 0.0007, pc = 0.01 respectively). "
|2.||Psoriasis (Pustulosis Palmaris et Plantaris)
09/01/2011 - "Furthermore, the frequencies of HLA-A28 (OR-0.074, P=0.0024), B5 (OR-0.059, P<0.0001), B12 (OR-0.051, P=0.0002), and B15 (OR-0.237, P=0.0230) were significantly decreased in psoriasis patients. "
09/01/2011 - "This study shows the strong association of HLA-A2, B8, and B17 antigens with psoriasis conferring susceptibility to psoriasis patients from Western India, while the antigens HLA-A28, B5, and B12 show strong negative association with the disease."
|3.||Genetic Predisposition to Disease (Genetic Predisposition)
06/01/1997 - "These results confirm the role of HLA-DR4 (DRB1*0407) in the genetic susceptibility to AP and raise the possibility of a role for class I MHC antigens HLA-A28 and B16 in Mexican patients."
03/01/1996 - "A genetic predisposition to this disease has been reported in subjects with phenotype HLA-DR3, -DR4, -A1, -B8 or HLA-A28, -B8; a phenotype HLA-B8 has been described in subjects with adrenal autoantibodies (AA) not progressing toward an overt disease. "
|4.||Melanoma (Melanoma, Malignant)
07/01/1993 - "Of the 28 cytolytic CD8+ T cell clones, 21 lysed the autologous melanoma cell line (M7) but not the autologous lymphoblastoid cell line (LCL-7) nor the two melanoma cell line, M1 (HLA A28) and M2 (HLA A28, A31), used to immunize the patient. "
04/15/2002 - "An association between expression of > or = two of five HLA class I antigens (HLA-A2, HLA-A28, HLA-B44, HLA-B45, and HLA-C3; collectively called M5) and response to an allogeneic melanoma vaccine (Melacine; Corixa Corporation, Seattle, WA) has been described in stage IV melanoma. "
01/01/1987 - "In the group including 'combined', 'prehypertensive', 'atopic' alopecia of Ikeda's classification the frequency of HLA-A28 and DR5 was increased and that of DR1 was decreased in comparison with the 'common' type of alopecia and the controls. "
06/01/1988 - "Compared with the normal subjects, HLA-A28 was more frequent in the patients with hypoparathyroidism (31%; P less than 0.001, corrected P less than 0.04), adrenocortical failure (27%; P less than 0.01), insulin-dependent diabetes mellitus (IDDM; 66%; P less than 0.01), keratopathy (53%; P less than 0.001, corrected P less than 0.04), and alopecia (40%; P less than 0.001, corrected P less than 0.04), but not in the patients with ovarian failure (9%; P = NS). "
|2.||HLA-B8 Antigen (HLA B8 Antigen)
|4.||HLA-A2 Antigen (HLA A2 Antigen)
|8.||HLA-DR4 Antigen (HLA DR4 Antigen)
|9.||HLA-DR3 Antigen (HLA DR3 Antigen)
|10.||HLA-B35 Antigen (HLA B35 Antigen)